A new therapy improves transplant rates and outcomes for patients awaiting living- and deceased-donor kidney transplantation. The therapy may provide an option for many patients "sensitized" to transplant antigens (human leukocyte antigens, or HLA) who previously would not have been candidates for transplantation because of their intense immune response to these HLA targets.
More...